Skip to main content



shares gained Tuesday as the drugmaker said the Food and Drug administration has agreed to review its new drug application for its treatment of invasive fungal infection.

The New Jersey-based company said its posaconazole oral suspension is a new chemical entity that exhibits potent antifungal activity in vitro against a wide range of fungal pathogens, including both yeasts and molds.

TheStreet Recommends

"Posaconazole provides an oral therapy option for these serious infections caused by a variety of fungal organisms, including those resistant to other drugs," the company said in a statement.

Invasive fungal infections most often occur in severely immunocompromised patients, such as organ transplant patients or cancer patients undergoing chemotherapy.

Schering also plans to file a similar new drug application with European regulators.

Shares rose 35 cents, or 2%, to $17.90 in premarket trading.